Now Available - More than a test
 

SARS-CoV-2 PCR testing with enhanced gene coverage in just 20 minutes*

 

Speed, plus

The NEW Xpert® Xpress CoV-2 plus test provides fast and accurate results in as early as 20 minutes. Get actionable, rapid respiratory results for efficient patient management.
 

Accuracy, plus

The NEW Xpert® Xpress CoV-2 plus test provides a third gene target for SARS-CoV-2 as well as an optimization of nucleocapsid gene probes to enable more reliable virus detection and further mitigate the possible effects of viral mutations.

Peace of mind

The NEW Xpert® Xpress CoV-2 plus test has been designed to give healthcare providers lab-quality results in a point of care setting with a simplified workflow for testing symptomatic and asymptomatic patients.

 

Choose the PCRplus advantage. 
Get MORE than results.
 

CE-IVD. In Vitro Diagnostic Medical Device. May not be available in all countries.
* The Xpert Xpress CoV-2 plus test includes an Early Assay Termination (EAT) function, which will provide earlier time to results in as little as 20 minutes for positives when running SARS-CoV-2; otherwise, the test will have a runtime of approximately 30 minutes.

Find out about Cepheid’s respiratory offering

*required fields
Cepheid respects your privacy, and values the relationship with our customers, partners, and associates. Your personal data may be processed by Cepheid, its affiliates, representatives and other Danaher companies for business and marketing purposes. You can review Cepheid Privacy Policy online for additional information on your rights and how we use and share personal data we collect on our websites and other channels. Your consent to receiving Cepheid news can be withdrawn at any time. If you wish to unsubscribe from our mailing list, please click here. Building a relationship of trust is important to us and we will happily help with any questions on your personal data processing addressed to Privacy.officer@cepheid.com

About Cepheid

Cepheid is a leading molecular diagnostics company that is an operating company within Danaher Corporation’s (NYSE: DHR) Diagnostics platform.
Cepheid is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests.
By automating highly complex and time-consuming manual procedures, the company’s solutions deliver a better way for institutions of any size to perform sophisticated molecular diagnostic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer.

For more information, visit www.cepheid.com/en.


Cepheid Logo

©2022 Cepheid. All Rights Reserved.

Vira Solelh, 81470 Maurens-Scopont France | +33.563.825.300

YouTubeLinkedInTwitterFacebook